The Xeloda brand and generic had US sales of approximately USD 90m MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.
Dr. Reddy's Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.
Dr. Reddy's Laboratories is an integrated pharmaceutical company. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's major markets include USA, India, Russia and CIS countries, and Europe.
AstraZeneca and FibroGen provide update on FDA review of roxadustat
Quidel awarded FDA's EUA for prescribed QuickVue At-Home COVID-19 Test with results in ten minutes
QureBio's Q-1802 receives US FDA Investigational New Drug application approval
J&J waiting regulatory approval for new plant to deliver high volumes of COVID-19 vaccines to US
Novavax expects its COVID-19 vaccine to be authorised in US by May 2021
Inovio completes Phase II enrolment for US trail of COVID-19 vaccine candidate
US FDA Accepts US Merck's Gefapixant New Drug Application for Review
McKesson Begins Distributing the Johnson and Johnson COVID-19 Vaccine
Eurofins Launches At-Home COVID-19 PCR Test kit Available Direct to Consumers